Unknown

Dataset Information

0

Genetic variation of the IL-28B promoter affecting gene expression.


ABSTRACT: The current standard of care for the treatment of chronic hepatitis C is pegylated interferon-? (PEG-IFN?) and ribavirin (RBV). The treatment achieves a sustained viral clearance in only approximately 50% of patients. Recent whole genome association studies revealed that single nucleotide polymorphisms (SNPs) around IL-28B have been associated with response to the standard therapy and could predict treatment responses at approximately 80%. However, it is not clear which SNP is most informative because the genomic region containing significant SNPs shows strong linkage disequilibrium. We focused on SNPs in close proximity to the IL-28B gene to evaluate the function of each and identify the SNP affecting the IL-28B expression level most. The structures of IL-28A/B from 5' to 3'-UTR were determined by complete cDNA cloning. Both IL-28A and 28B genes consisted of 6 exons, differing from the CCDS data of NCBI. Two intron SNPs and a nonsynonymous SNP did not affect IL-28B gene function and expression levels but a SNP located in the proximal promoter region influenced gene expression. A (TA) dinucleotide repeat, rs72258881, located in the promoter region was discovered by our functional studies of the proximal SNPs upstream of IL-28B; the transcriptional activity of the promoter increased gradually in a (TA)(n) length-dependent manner following IFN-? and lipopolysaccharide stimulation. Healthy Japanese donors exhibited a broad range of (TA) dinucleotide repeat numbers from 10 to 18 and the most prevalent genotype was 12/12 (75%), differing from the database (13/13). However, genetic variation of IL-28A corresponding to that of IL-28B was not detected in these Japanese donors. These findings suggest that the dinucleotide repeat could be associated with the transcriptional activity of IL-28B as well as being a marker to improve the prediction of the response to interferon-based hepatitis C virus treatment.

SUBMITTER: Sugiyama M 

PROVIDER: S-EPMC3201970 | biostudies-literature | 2011

REPOSITORIES: biostudies-literature

altmetric image

Publications

Genetic variation of the IL-28B promoter affecting gene expression.

Sugiyama Masaya M   Tanaka Yasuhito Y   Wakita Takaji T   Nakanishi Makoto M   Mizokami Masashi M  

PloS one 20111025 10


The current standard of care for the treatment of chronic hepatitis C is pegylated interferon-α (PEG-IFNα) and ribavirin (RBV). The treatment achieves a sustained viral clearance in only approximately 50% of patients. Recent whole genome association studies revealed that single nucleotide polymorphisms (SNPs) around IL-28B have been associated with response to the standard therapy and could predict treatment responses at approximately 80%. However, it is not clear which SNP is most informative b  ...[more]

Similar Datasets

| S-EPMC4273403 | biostudies-literature
| S-EPMC3359351 | biostudies-literature
| S-EPMC2689933 | biostudies-literature
| S-EPMC5861906 | biostudies-literature
| S-EPMC3859948 | biostudies-literature
| S-EPMC2735003 | biostudies-literature
| S-EPMC1194932 | biostudies-literature
| S-EPMC8557422 | biostudies-literature
| S-EPMC4017648 | biostudies-literature
| S-EPMC3554614 | biostudies-literature